Healthcare Industry News:  Sanofi 

Biopharmaceuticals Dermatology Mergers & Acquisitions

 News Release - December 19, 2011

Valeant Pharmaceuticals Completes Acquisition of Dermik

MISSISSAUGA, Ontario , Dec. 19, 2011 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that effective December 16, 2011 , the company completed its previously announced acquisition of Dermik, a dermatology unit of Sanofi (EURONEXT: SAN and NYSE: SNY).

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.


Source: Valeant Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.